23 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
categories, with 50% of an executive’s bonus opportunity tied to the achievement of TCR innovation metrics, 40% tied to business growth metrics and 10% tied …
Achievement
Lead in TCR Innovation
Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
, with 50% of an executive’s bonus opportunity tied to the achievement of TCR innovation metrics, 40% tied to business growth metrics and 10% tied …
Achievement
Lead in TCR Innovation
Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
secrets and know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and know-how … application.
Biosimilars and Exclusivity
The Biologics Price Competition and Innovation Act, or BPCIA, established a regulatory scheme authorizing the FDA
6-K
EX-99.2
IMCR
Immunocore Holdings plc
20 Jul 22
Securities Purchase Agreement
4:06pm
, M.D.
Title:
Director
RTW INNOVATION MASTER FUND, LTD.
By:
/s/
Roderick Wong, M.D
Name:
Roderick Wong, M.D.
Title:
Director
RTW VENTURE FUND LIMITED
6-K
EX-99.1
IMCR
Immunocore Holdings plc
20 Jul 22
Securities Purchase Agreement
4:06pm
Wong, M.D.
Name:
Roderick Wong, M.D.
Title:
Director
RTW INNOVATION MASTER FUND, LTD.
By:
/s/ Roderick Wong, M.D.
Name:
Roderick Wong, M.D.
Title
6-K
EX-99.1
nt3tn6 wn7xwyhz
9 Jun 22
Immunocore Appoints Siddharth Kaul to its Board of Directors
4:12pm
6-K
EX-99.2
ol1g9dtf6
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.3
6t8lz51
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.1
ju188rap9h2n3 rb
24 Aug 21
Current report (foreign)
4:33pm
6-K
EX-99.3
pqn4ktjpcb7oz
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
20-F
8zu xcholm
25 Mar 21
Annual report (foreign)
7:01am
424B4
nbxld378
8 Feb 21
Prospectus supplement with pricing info
8:36am
F-1/A
4c0aet7h
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
F-1/A
knzft8syt r56mfbfdxt
1 Feb 21
Registration statement (foreign) (amended)
6:21am
F-1
EX-10.6
rtinewr96 d7
15 Jan 21
Registration statement (foreign)
4:57pm
F-1
EX-10.15
841ltcp wtwz6cx1
15 Jan 21
Registration statement (foreign)
4:57pm
F-1
mcgayo9wigm072u8dd
15 Jan 21
Registration statement (foreign)
4:57pm
DRS/A
EX-10.14
r13q o5p72uts
22 Dec 20
Draft registration statement (amended)
12:00am